UA93647U - Method for treating bronchial asthma in patients with latent course of ischemic heart disease - Google Patents
Method for treating bronchial asthma in patients with latent course of ischemic heart diseaseInfo
- Publication number
- UA93647U UA93647U UAU201404697U UAU201404697U UA93647U UA 93647 U UA93647 U UA 93647U UA U201404697 U UAU201404697 U UA U201404697U UA U201404697 U UAU201404697 U UA U201404697U UA 93647 U UA93647 U UA 93647U
- Authority
- UA
- Ukraine
- Prior art keywords
- heart disease
- ischemic heart
- bronchial asthma
- patients
- course
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title abstract 4
- 208000031225 myocardial ischemia Diseases 0.000 title abstract 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000001771 impaired effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010049765 Bradyarrhythmia Diseases 0.000 abstract 1
- 208000001871 Tachycardia Diseases 0.000 abstract 1
- 208000006218 bradycardia Diseases 0.000 abstract 1
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 abstract 1
- 229960003825 ivabradine Drugs 0.000 abstract 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 abstract 1
- 229960002497 nicorandil Drugs 0.000 abstract 1
- 230000002336 repolarization Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000006794 tachycardia Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The method for treating the bronchial asthma in the patients with the latent course of the ischemic heart disease comprises the use of antihypoxant therapy in the setting of the basic therapy of the bronchial asthma. In the case of low-symptom course of the ischemic heart disease with the impaired repolarization phase, Cratal is prescribed for 4 weeks. In the case of arhythmogenic ischemic heart disease without ST depression with tachycardia syndrome. Coraxan is prescribed for 3 weeks. In bradyarrhythmia with the impaired conductivity and asthma attacks in the night, Nicorandil is prescribed for 14 days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201404697U UA93647U (en) | 2014-05-05 | 2014-05-05 | Method for treating bronchial asthma in patients with latent course of ischemic heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201404697U UA93647U (en) | 2014-05-05 | 2014-05-05 | Method for treating bronchial asthma in patients with latent course of ischemic heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA93647U true UA93647U (en) | 2014-10-10 |
Family
ID=56277572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201404697U UA93647U (en) | 2014-05-05 | 2014-05-05 | Method for treating bronchial asthma in patients with latent course of ischemic heart disease |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA93647U (en) |
-
2014
- 2014-05-05 UA UAU201404697U patent/UA93647U/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (en) | NEW METHODS. | |
| CL2015003731A1 (en) | Bromodomain Inhibitors | |
| CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
| MX2021000071A (en) | Use of pridopidine to improve cognitive function and for treating alzheimer's disease. | |
| HK1220980A1 (en) | Methods and compositions for treatment of pompe disease | |
| EA201790398A1 (en) | METHODS OF TREATING LIVER DISEASES | |
| EA201491584A1 (en) | METHODS OF TREATING NON-SMALL-CELL LUNG CANCER WITH THE USE OF COMBINED TREATMENT WITH KINASE TOR INHIBITOR | |
| MX386595B (en) | METHODS FOR THE TREATMENT OF OVERWEIGHT OR OBESITY. | |
| BR112015029386A2 (en) | use of eribulin and lenvatinib as combination therapy for cancer treatment | |
| MX2017015226A (en) | TETRASUSTITUID ALQUENO COMPOUNDS AND ITS USE. | |
| SG195110A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
| MX374944B (en) | PYRANOCROMENYL PHENOL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME OR INFLAMMATORY DISEASE. | |
| BR112015023439A2 (en) | combination of cancer treatments using micro-ovens and egfr-tki inhibitors | |
| MY179105A (en) | Methods of treating alzheimer's disease | |
| EA201790563A8 (en) | APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY | |
| BR112017014361A2 (en) | methods for perfecting cell therapy | |
| EA201690964A1 (en) | COMPOSITIONS AND METHODS FOR REDUCING SERIOUS ADVERSE CARDIOVASCULAR PHENOMENA | |
| BR112016015997A2 (en) | ? PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND 15- HEPE AND METHODS TO TREAT ASTHMA AND PULMONARY DISORDERS WITH THE USE OF THEM? | |
| BR112015010039A2 (en) | treatment of cancer with pomalidomide in an individual with renal dysfunction | |
| EA032271B9 (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| MY176219A (en) | Combination therapy for cancer | |
| MX2016014859A (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases. | |
| MX2019000677A (en) | B-cell-mimetic cells. | |
| MX2018005035A (en) | Sustained release formulations of local anesthetics. |